Prophylactic activity of increasing doses of intravenous histamine in refractory migraine: Retrospective observations of a series of patients with migraine without aura

Current Therapeutic Research - Clinical and Experimental

Volumn 65, Issue 1, 2004, Pages 70-78

  Pietrini, Umberto ^a   De Luca, Massimo ^a,b   Del Bene, Enrico ^a,b   De Cesaris, Francesco ^a,b   Bertinotti, Luca ^b   Colangelo, Nicola ^b   Moggi Pignone, Alberto ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Istituto di Clinica Medica IV   (Italy)

Author keywords

histamine; migraine; prophylaxis

Indexed keywords

HISTAMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EPILEPTIC AURA; FEMALE; FLUSHING; HEADACHE; HEART PALPITATION; HEAT SENSATION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MALE; MIGRAINE; OPEN STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SIDE EFFECT;

EID: 3242737469     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(04)90006-9     Document Type: Article

References (36)

1. Brown R.E., Stevens D.R., Haas H.L. The physiology of brain histamine. Progr Neurobiol. 63:2001;637-672
2. Lassen L.H., Ashina M., Christiansen I., et al. Nitric oxide synthase inhibition: A new principle in th treatment of migraine attacks. Cephalalgia. 18:1998;27-32
3. Thomsen L.L. Investigations into the role of nitric oxide and the large intracranial arteries in migraine headache. Cephalalgia. 17:1997;873-895
4. Akerman S., Williamson D.J., Kaube H., Goadsby P.J. The role of histamine in dural vssel dilation. Brain Res. 956:2002;96-102
5. Olesen J., Jansen-Olesen I. Nitric oxide mechanisms in migraine. Pathol Biol (Paris). 48:2000;648-657
6. Akerman S., Williamson D.J., Kaube H., Goadsby P.J. The effect of anti-migraine compounds on nitric-oxide induced dilation of dural meningeal vessels. Eur J Pharmacol. 452:2002;223-228
7. Edvinsson L., Goadsby P.J. Neuropeptides in migraine and cluster headache. Cephalalgia. 14:1994;320-327
8. Moskowitz M.A. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology. 43:(Suppl 3):1993;S16-S20
9. Goadsby P.J., Edvinsson L., Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 28:1990;183-187
10. 2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience. 89:1999;901-907
11. Diamond S., Medina J.L. Double blind study of propranolol for migraine prophylaxis. Headache. 16:1976;24-27
12. al-Qassab H.K., Findley L.J. Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: A placebo controlled study. Cephalalgia. 13:1993;128-131
13. Havanka-Kanniainen H., Hokkanen E., Myllylä V.V. Long acting propranolol in the prophylaxis of migraine. Comparison of the daily doses of 80 mg and 160 mg. Headache. 28:1988;607-611
14. Kangasniemi P., Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. Cephalalgia. 4:1984;91-96
15. Centonze V., Magrone D., Vino M., et al. Flunarizine in migraine prophylaxis: Efficacy and tolerability of 5 mg and 10 mg dose levels. Cephalalgia. 10:1990;17-24
16. Louis P., Spierings E.L. Comparison of flunarizine (Sibelium) and pizotifen (Sandomigran) in migraine treatment: A double-blind study. Cephalalgia. 2:1982;197-203
17. Diener H.C., Matias-Guiu J., Hartung E., et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: A comparison with propranolol 160 mg daily. [published correction appears in Cephalalgia. 2002;22:488] Cephalalgia. 22:2002;209-221
18. Bank J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache. 34:1994;476-478
19. Ziegler D.K., Hurwitz A., Hassanein R.S., et al. Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol. 44:1987;486-489
20. d'Amato C.C., Pizza V., Marmolo T., et al. Fluoxetine for migraine prophylaxis: A doubleblind trial. Headache. 39:1999;716-719
21. Steiner T.J., Ahmed F., Findley L.J., et al. S-fluoxetine in the prophylaxis of migraine: A phase II double-blind randomized placebo-controlled study. Cephalalgia. 18:1998;283-286
22. Freitag F.G., Collins S.D., Carlson H.A. Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 58:2002;1652-1659
23. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 8:(Suppl 7):1988;1-96
24. Fanciullacci M., Boccuni M., Pietrini U., Gatto G. Pupil and vein as detectors of neuronal mechanisms of antimigraine drugs. Emery W.K., Van Neuten J.M., Wauquier A. The Pharmacological Basis of Migraine Therapy. 1984;239-252 Pitman, London
25. Fanciullacci M. Iris adrenergic impairment in idiopathic headache. Headache. 19:1979;8-13
26. Kunkle E.C., Anderson W.B. Significance of minor eye signs in headache of migraine type. Arch Ophthalmol. 65:1961;504-508
27. Guerrero R.O., Cardenas M.A., Ocampo A.A., Pacheco M.F. Histamine as a therapeutic alternative in migraine prophylaxis: A randomized, placebo-controlled, double-blind study. Headache. 39:1999;576-580
28. Millan-Guerrero R.O., Pineda-Lucatero A.G., Hernandez-Benjamin T., et al. Nα-methylhistamine safety and efficacy in migraine prophylaxis: Phase I and phase II studies. Headache. 43:2003;389-394
29. Eriksson K.S., Stevens D.R., Haas H.L. Opposite modulation of histaminergic neurons by nociceptin and morphine. Neuropharmacology. 39:2000;2492-2498
30. Glick S.D., Crane L.A. Opiate-like and abstinence-like effects of intracerebral histamine administration in rats. Nature. 273:1978;547-549
31. Thoburn K.K., Hough L.B., Nalwalk J.W., Mischler S.A. Histamine-induced modulation of nociceptive responses. Pain. 58:1994;29-37
32. Malmberg-Aiello P., Lamberti C., Ghelardini C., et al. Role of histamine in rodent antinociception. Br J Pharmacol. 111:1994;1269-1279
33. Malmberg-Aiello P., Lamberti C., Ipponi A., et al. Effects of two histamine-N-ethyltransferase inhibitors, SKF 91488 and BW 301 U, in rodent antinociception. Naunyn-Schmiedebergs Arch Pharmacol. 355:1997;354-360
34. 3 receptor agonist prodrug. J Pharmacol Exp Ther. 281:1997;1085-1094
35. 3 receptors and the pharmacology of its ligands. [in Japanese] Nihon Shinkei Seishin Yakurigaku Zasshi. 15:1995;87-102
36. Anselmi B., Tarquini R., Panconesi A., et al. Serum beta-endorphin increase after intravenous histamine treatment of chronic daily headache. Recenti Prog Med. 88:1997;321-324